ARS Pharmaceuticals, Inc (SPRY) — Cash Flow Reinvestment Rate
ARS Pharmaceuticals, Inc (SPRY) has a Cash Flow Reinvestment Rate of 2.43x as of December 2024, reinvesting $102.06 Million (capex $302.00K plus investments $-101.76 Million) from operating cash flow of $42.00 Million. Check ARS Pharmaceuticals, Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
ARS Pharmaceuticals, Inc Cash Flow Reinvestment Rate (2020–2024)
Historical reinvestment intensity for ARS Pharmaceuticals, Inc across 2 annual periods. Explore SPRY operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for ARS Pharmaceuticals, Inc (2020–2024)
Year-by-year capital reinvestment analysis for ARS Pharmaceuticals, Inc. For live market cap and broader valuation context, see ARS Pharmaceuticals, Inc (SPRY) total market value.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 7.87x | $106.66 Million | $13.55 Million | $563.00K | ▲ +7688.0% |
| 2020 | 0.10x | $917.00K | $9.07 Million | $917.00K | — |